Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...

Vertex, Inc. (NASDAQ:VERX) Q3 2024 Earnings Call Transcript ... I left both events extremely energized and convinced that we ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) and keeping the price ...

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.

US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s ...

Explore Claude 3.5 Haiku's strengths, limitations, and market implications in the AI landscape. Uncover the future of AI with ...

Citigroup's financial infrastructure powers much of the global economy, but is difficult to upgrade. A move to Google Cloud ...

Hello and thanks for joining us to discuss Vertex Inc third quarter financial results. I'm Joe Crivelli, Vice President, Investor Relations, David DiStefano, our President and CEO and John Schwab. Our ...

(Reuters) - Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsJoe Crivelli - Vice President, ...